Iron-deficiency anemia

The Inner Circle acknowledges Amir A. Rasheed as a Distinguished Healthcare Professional

Retrieved on: 
Thursday, March 7, 2024
Houston Methodist West Hospital, Inner circle, Iron-deficiency anemia, Multimedia, Houston Methodist Baytown Hospital, Hematology, Blood, North Shore University Hospital, Dow Medical College, SUNY Downstate Medical Center, St Luke's, State university system, Prognosis, Haemophilia, Internal medicine, Leukemia, Patient, Oncology, Medicine, Multiple myeloma, Medical Center, Diagnosis, Anti-transglutaminase antibodies, Lymphoma, Cancer, Hospital

SUGARLAND, Texas, March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir A. Rasheed is acknowledged as a Distinguished Healthcare Professional for his contributions to the fields of Oncology and Hematology.

Key Points: 
  • SUGARLAND, Texas, March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir A. Rasheed is acknowledged as a Distinguished Healthcare Professional for his contributions to the fields of Oncology and Hematology.
  • Dr. Rasheed pursued his medical education at Dow Medical College where he earned a medical degree.
  • He then relocated to the United States to complete a residency in internal medicine at the State University of New York Health Science Center at Brooklyn.
  • Known for his compassionate care and clinical excellence, Dr. Rasheed has dedicated his life to delivering the highest standard of quality care to his patients.

The Inner Circle Acknowledges, James C. Lasker as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Hematology-Oncology

Retrieved on: 
Tuesday, September 5, 2023
Lymphoma, Emory University, Yale University, Medical school, Physician, Education, Internal medicine, Friends, Temple University, Hematology, American Board of Internal Medicine, ABIM, American Society of Clinical Oncology, Baylor University, Cancer, Haemophilia, Prognosis, Partner (business rank), Mentorship, American Society of Hematology, Inner circle, Oncology, Baptists, American Board of Commissioners for Foreign Missions, Iron-deficiency anemia, Patient, Blood, School, BPA, Fellow, MD Anderson Cancer Center, California Community College Athletic Association, Anti-transglutaminase antibodies, Baylor College of Medicine, Diagnosis, Leukemia, American Society of Pediatric Hematology/Oncology, Society, Dentistry, Nursing, MD, Princeton University, Biology, Medicine

VERO BEACH, Fla., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James C. Lasker is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Hematology-Oncology.

Key Points: 
  • VERO BEACH, Fla., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James C. Lasker is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Hematology-Oncology.
  • Dr. Lasker pursued higher education at Yale University where he earned a Bachelor of Science degree in Biology.
  • He also noted that oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
  • The doctor would like to dedicate this honor to his mentors, Monty Lane, MD; Ken Walker, MD; and Jimmie Harvey, MD.

The Inner Circle Acknowledges, Amir Rasheed as a Top Pinnacle Healthcare Professional for his contributions to the fields of Oncology and Hematology

Retrieved on: 
Tuesday, June 20, 2023
Lymphoma, SUNY Downstate Medical Center, Internal medicine, Dow Medical College, Hematology, Multiple myeloma, American Board of Internal Medicine, ABIM, State university system, Cancer, Haemophilia, St Luke's, Prognosis, Medicine, Multimedia, Inner circle, Oncology, Houston Methodist West Hospital, American Board of Commissioners for Foreign Missions, Iron-deficiency anemia, Patient, Houston Methodist Sugar Land Hospital, Baylor St. Luke's Medical Center, Medical Center, Blood, Anti-transglutaminase antibodies, Diagnosis, Leukemia, Houston Methodist Baytown Hospital, Nursing

SUGARLAND, Texas, June 20, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir Rasheed is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the fields of Oncology and Hematology.

Key Points: 
  • SUGARLAND, Texas, June 20, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir Rasheed is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the fields of Oncology and Hematology.
  • Dr. Rasheed pursued his medical education at Dow Medical College where he earned a medical degree.
  • He then relocated to the United States to complete a residency in internal medicine at the State University of New York Health Science Center at Brooklyn.
  • Known for his compassionate care and clinical excellence, Dr. Rasheed has dedicated his life to delivering the highest standard of quality care to his patients.

Fight Fatigue, Optimize Energy and Feel Restored With Fergon Iron Restore Now at Rite Aid and H-E-B

Retrieved on: 
Wednesday, August 31, 2022
Health, Manufacturing, Other Health, Fitness & Nutrition, General Health, Other Manufacturing, Vitamins, Supplements, OTC, Program, DSE, Iron deficiency, Council, Iron, CHPA, Collection, Iron-deficiency anemia, Rite Aid, Multimedia, Association, Council for Responsible Nutrition, Constipation, CRN, LLC, Operation Blessing International, Woman, Health, Dietary supplement, Pharmaceutical industry, Iron supplement

Fergon Iron Restore , the iron supplement 8 out of 10 people prefer1, is thrilled to announce new retail distribution at Rite Aid and H-E-B .

Key Points: 
  • Fergon Iron Restore , the iron supplement 8 out of 10 people prefer1, is thrilled to announce new retail distribution at Rite Aid and H-E-B .
  • Fergon Iron Restore, made and manufactured in the U.S. by DSE Healthcare Solutions, provides 150% of the daily recommended value of iron.
  • With the new distribution at Rite Aid and H-E-B, this program will increase exponentially; for every package of Fergon Iron Restore purchased at Rite Aid and H-E-B locations, DSE will donate additional iron supplements and other essential resources to Operation Blessing .
  • Head over to your local Rite Aid or H-E-B store to purchase Fergon Iron Restore and help give back to Operation Blessing.

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022
MDS, Woman, Intellectual property, U.S. Securities and Exchange Commission, Risk, Lists of diseases, Disorder, Part, Trial of the century, GLOBE, Iron-deficiency anemia, TI, Hypertensive emergency, Private Securities Litigation Reform Act, Microdeletion syndrome, SEC, DLT, Alkaline phosphatase, Growth, BSAP, Achievement, Security (finance), KROS, Research, MAD, Osteoporosis, Patient, European Hematology Association, Therapy, COVID-19, Company, Șaeș, MF, Safety, Reticulocyte, Anemia, Iron overload, Maintenance, Bone loss, Erythropoiesis, Protein, PAH, Ruxolitinib, HTB, Osteogenesis imperfecta, BMP, Thrombocytopenia, Cytopenia, SAE, Pharmaceutical industry, Medical imaging, Vaccine, Dietary supplement

LEXINGTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary, and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the quarter ended June 30, 2022.

Key Points: 
  • We continued the positive momentum for our pipeline programs into the second quarter of 2022.
  • In May 2022, Keros announced preliminary topline data from the Phase 1 clinical study of KER-012 in healthy postmenopausal women.
  • Keros reported a net loss of $27.3 million in the second quarter of 2022 as compared to a net loss of $15.6 million in the second quarter of 2021.
  • Research and development expenses were $23.3 million for the second quarter of 2022 as compared to $10.0 million for the same period in 2021.

Penn Dental Medicine Study Finds 'Nanozyme' Therapy Prevents Dental Plaque Buildup

Retrieved on: 
Wednesday, April 6, 2022
Plaque, Indiana University, Multimedia, Bacteria, Nano Letters, Research, Nanoparticle, School, View, Innovation, Tooth decay, Center, Infection, Iron-deficiency anemia, Nature Communications, Hydrogen peroxide, Penns, Radioactive decay, FDA, Perelman School of Medicine at the University of Pennsylvania, Dentistry, Medicine

Now, research from Penn Dental Medicine , in collaboration with Indiana University , suggests that an FDA-approved therapy for iron-deficiency anemia also holds promise for treating, preventing, and even diagnosing tooth decay-causing plaque.

Key Points: 
  • Now, research from Penn Dental Medicine , in collaboration with Indiana University , suggests that an FDA-approved therapy for iron-deficiency anemia also holds promise for treating, preventing, and even diagnosing tooth decay-causing plaque.
  • "We found that this approach is both precise and effective," says Dr. Michel Koo , a professor atPenn Dental Medicine and Co-Director of the School's Center for Innovation & Precision Dentistry.
  • "It disrupts dental biofilms (plaque), particularly those that cause caries, and it also reduced the extent of enamel decay.
  • This is the first study we know of done in a clinical setting that demonstrates the therapeutic value of nanozymes against an infectious disease."

Blood Disorders Pipeline Database 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 2, 2021
Health, General Health, Disorder, Haemophilia A, Degenerative disease, Haemophilia B, View, Iron-deficiency anemia, Anti-transglutaminase antibodies, Database, Dietary supplement, Pharmaceutical industry

The "Blood Disorders Pipeline Database - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Disorders Pipeline Database - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Blood Disorders Pipeline Highlights Database - 2021, provides the most up-to-date information on key pipeline products in the global Blood Disorders Drug market.
  • By Drug Mechanism Classes: The database provides Blood Disorders pipeline products by their dominant drug mechanism class.
  • By Company: The database provides Blood Disorders pipeline products by the company.

Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1

Retrieved on: 
Thursday, August 5, 2021
Biotechnology, Pharmaceutical, Health, Iron-deficiency anemia, Growth, United States dollar, Manuscript, ANCA, Board, Annual, Marketing, Scd, Income, Hospital, Kidney, Blood, Earnings before interest, taxes, depreciation and amortization, Erythropoiesis-stimulating agent, Review, European Medicines Agency, EMA, Cer, Food and Drug Administration, The New England Journal of Medicine, Sickle cell disease, Therapy, Group, CKD, Anemia, Population, Iron, Mortality, Advisory Committee, European Heart Journal, Depreciation, Dialysis, Raasi, Vifor Pharma, File, Quality of life, Leadership, Hyperkalemia, Awareness, European Space Agency, Pharma, Heart failure, Prescription Drug User Fee Act, Adoption, Annual general meeting, Maa, Executive Committee, Patient, COVID-19, PBM, CHF, NDA, Director, Overalls, Heart, Pharmaceutical industry, Medical device, Aquaculture

Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance.

Key Points: 
  • Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance.
  • Ferinject / Injectafer net sales increased 22.4% (up 22.8% at CER) to CHF 320.5 million in H1 2021 from CHF 261.9 million a year earlier.
  • As a result, Vifor Pharma posted net sales of CHF 73.7 million, up 1.4% or 8.5% at CER.
  • Abbas Hussain was appointed Chief Executive Officer of Vifor Pharma, succeeding Stefan Schulze, who has decided to step down for personal reasons.

Sandoz launches first generic high dose intravenous iron, Ferumoxytol Injection, to treat US patients with iron deficiency anemia

Retrieved on: 
Friday, July 16, 2021
Chemistry, Natural sciences, Life sciences, Biosimilar, Biotechnology, Drugs, Iron(II,III) oxide, Iron-deficiency anemia

PRINCETON, N.J., July 16, 2021 /PRNewswire/ --Sandoz, a global leader in generic and biosimilar medicines, today announced the immediate US availability of generic Ferumoxytol, an intravenous medicine used to treat iron deficiency anemia (IDA).

Key Points: 
  • PRINCETON, N.J., July 16, 2021 /PRNewswire/ --Sandoz, a global leader in generic and biosimilar medicines, today announced the immediate US availability of generic Ferumoxytol, an intravenous medicine used to treat iron deficiency anemia (IDA).
  • Sandoz initially plans to make its generic Ferumoxytol medicine available to patients in the hospital and clinic setting.
  • Ferumoxytol is contraindicated in patients with:
    Hypersensitivity Reactions: Observe for signs and symptoms of hypersensitivity for at least 30 minutes following the administration of Ferumoxytol.
  • Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical need.

Lucky Iron Fish receives $250k in funding to help address iron deficiency anemia in Benin.

Retrieved on: 
Wednesday, June 30, 2021
Mineral deficiencies, Nutrition, Chemistry, Iron metabolism, Physical sciences, Iron-deficiency anemia, Lucky iron fish, Iron deficiency, Iron, Anemia

Toronto, June 30, 2021 (GLOBE NEWSWIRE) -- Lucky Iron Fish Enterprise (LIFe) is an impact-driven company that is on a mission to tackle iron deficiency globally using their innovative solutions designed to make iron intake more accessible to more people.

Key Points: 
  • Toronto, June 30, 2021 (GLOBE NEWSWIRE) -- Lucky Iron Fish Enterprise (LIFe) is an impact-driven company that is on a mission to tackle iron deficiency globally using their innovative solutions designed to make iron intake more accessible to more people.
  • For this project, LIFe will be working with their long-termpartners at CARE Benin .With the help of the $250,000 funding, they will provide nutrition workshops and introduce the Lucky Iron Fish as a recommended addition to daily cooking in order to reduce prevalence of iron deficiency anemia.
  • Iron deficiency is a global health issue that impacts 1 out of 3 individuals (2+ billion worldwide), with women, girls, and children impacted at a disproportionately higher rate.
  • In Benin alone, 62% of children under 5 and 47% of females of reproductive age suffer from iron deficiency anemia.